vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and TOWER SEMICONDUCTOR LTD (TSEM). Click either name above to swap in a different company.
TOWER SEMICONDUCTOR LTD is the larger business by last-quarter revenue ($351.2M vs $177.4M, roughly 2.0× Pacira BioSciences, Inc.). TOWER SEMICONDUCTOR LTD runs the higher net margin — 15.2% vs 1.6%, a 13.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -1.7%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Tower Semiconductor Ltd. is an Israeli company that manufactures integrated circuits using specialty process technologies, including SiGe, BiCMOS, Silicon Photonics, SOI, mixed-signal and RFCMOS, CMOS image sensors, non-imaging sensors, power management (BCD), and non-volatile memory (NVM) as well as MEMS capabilities. Tower Semiconductor also owns 51% of TPSCo, an enterprise with Nuvoton Technology Corporation Japan (NTCJ).
PCRX vs TSEM — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $351.2M |
| Net Profit | $2.9M | $53.4M |
| Gross Margin | — | 24.8% |
| Operating Margin | 3.9% | 15.7% |
| Net Margin | 1.6% | 15.2% |
| Revenue YoY | 5.0% | -1.7% |
| Net Profit YoY | — | 4.4% |
| EPS (diluted) | $0.07 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | — | ||
| Q3 25 | $179.5M | — | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | — | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | — | ||
| Q2 24 | $178.0M | $351.2M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | — | ||
| Q2 24 | $18.9M | $53.4M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | 24.8% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | — | ||
| Q2 24 | 15.9% | 15.7% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | — | ||
| Q2 24 | 10.6% | 15.2% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $265.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $2.5B |
| Total Assets | $1.2B | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | $265.3M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | — | ||
| Q3 25 | $727.2M | — | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | — | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | — | ||
| Q2 24 | $879.3M | $2.5B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | $3.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TSEM
Segment breakdown not available.
